Iniparib News and Research

RSS
New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

New TripAdvisor-style website launched to help researchers choose better tools for biomedical research

Scientists find new way to predict response to platinum-based chemotherapy in women with triple-negative breast cancer

Scientists find new way to predict response to platinum-based chemotherapy in women with triple-negative breast cancer

Survey reveals high interest in Xalkori among medical oncologists

Survey reveals high interest in Xalkori among medical oncologists

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Iniparib Phase III study in metastatic triple-negative breast cancer does not meet primary goal

Study shows clinical benefits of iniparib in combination with standard chemotherapy for triple-negative breast cancer

Study shows clinical benefits of iniparib in combination with standard chemotherapy for triple-negative breast cancer

Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer

Sanofi-aventis announces publication of positive BSI-201 phase II results for breast cancer

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

A new treatment landscape for triple-negative breast cancer

A new treatment landscape for triple-negative breast cancer

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019